A Consensus Prognostic Gene Expression Classifier for ER Positive Breast Cancer

Overview

Journal Genome Biol

Specialties Biology
Genetics

Date 2006 Nov 2

PMID 17076897

Citations 49

Authors

Andrew E Teschendorff

Ali Naderi

Nuno L Barbosa-Morais

Sarah E Pinder

Ian O Ellis

Sam Aparicio

James D Brenton

Carlos Caldas

Affiliations

Soon will be listed here.

Abstract

Background: A consensus prognostic gene expression classifier is still elusive in heterogeneous diseases such as breast cancer.

Results: Here we perform a combined analysis of three major breast cancer microarray data sets to hone in on a universally valid prognostic molecular classifier in estrogen receptor (ER) positive tumors. Using a recently developed robust measure of prognostic separation, we further validate the prognostic classifier in three external independent cohorts, confirming the validity of our molecular classifier in a total of 877 ER positive samples. Furthermore, we find that molecular classifiers may not outperform classical prognostic indices but that they can be used in hybrid molecular-pathological classification schemes to improve prognostic separation.

Conclusion: The prognostic molecular classifier presented here is the first to be valid in over 877 ER positive breast cancer samples and across three different microarray platforms. Larger multi-institutional studies will be needed to fully determine the added prognostic value of molecular classifiers when combined with standard prognostic factors.

Citing Articles

Quick Automatic Synthesis of Solvent-Free 16α-[F] Fluoroestradiol: Comparison of Kryptofix 222 and Tetrabutylammonium Bicarbonate.

Jiang X, Li Y, Wang X, Shen T, Li X, Yao Y Front Oncol. 2020; 10:577979.

PMID: 33102235 PMC: 7546761. DOI: 10.3389/fonc.2020.577979.

EPISCORE: cell type deconvolution of bulk tissue DNA methylomes from single-cell RNA-Seq data.

Teschendorff A, Zhu T, Breeze C, Beck S Genome Biol. 2020; 21(1):221.

PMID: 32883324 PMC: 7650528. DOI: 10.1186/s13059-020-02126-9.

Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients.

Jablonska K, Grzegrzolka J, Podhorska-Okolow M, Stasiolek M, Pula B, Olbromski M Am J Cancer Res. 2016; 6(5):878-93.

PMID: 27293986 PMC: 4889707.

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.

Laas E, Mallon P, Duhoux F, Hamidouche A, Rouzier R, Reyal F PLoS One. 2016; 11(2):e0148957.

PMID: 26895349 PMC: 4760978. DOI: 10.1371/journal.pone.0148957.

Expression of a-Tocopherol-Associated protein (TAP) is associated with clinical outcome in breast cancer patients.

Wang X, Ring B, Seitz R, Ross D, Woolf K, Beck R BMC Clin Pathol. 2015; 15:21.

PMID: 26664297 PMC: 4673715. DOI: 10.1186/s12907-015-0021-5.

References

Segal E, Friedman N, Koller D, Regev A . A module map showing conditional activity of expression modules in cancer. Nat Genet. 2004; 36(10):1090-8. DOI: 10.1038/ng1434. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Royston P, Sauerbrei W . A new measure of prognostic separation in survival data. Stat Med. 2004; 23(5):723-48. DOI: 10.1002/sim.1621. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

Ein-Dor L, Kela I, Getz G, Givol D, Domany E . Outcome signature genes in breast cancer: is there a unique set?. Bioinformatics. 2004; 21(2):171-8. DOI: 10.1093/bioinformatics/bth469. View

Royston P, Parmar M, Sylvester R . Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med. 2004; 23(6):907-26. DOI: 10.1002/sim.1691. View

Hubbard T, Barker D, Birney E, Cameron G, Chen Y, Clark L . The Ensembl genome database project. Nucleic Acids Res. 2001; 30(1):38-41. PMC: 99161. DOI: 10.1093/nar/30.1.38. View

Pawitan Y, Bjohle J, Amler L, Borg A, Egyhazi S, Hall P . Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005; 7(6):R953-64. PMC: 1410752. DOI: 10.1186/bcr1325. View

Wang Y, Klijn J, Zhang Y, Sieuwerts A, Look M, Yang F . Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365(9460):671-9. DOI: 10.1016/S0140-6736(05)17947-1. View

10.

Rhodes D, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D . Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A. 2004; 101(25):9309-14. PMC: 438973. DOI: 10.1073/pnas.0401994101. View

11.

Ein-Dor L, Zuk O, Domany E . Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A. 2006; 103(15):5923-8. PMC: 1458674. DOI: 10.1073/pnas.0601231103. View

12.

Yeung K, Fraley C, Murua A, Raftery A, Ruzzo W . Model-based clustering and data transformations for gene expression data. Bioinformatics. 2001; 17(10):977-87. DOI: 10.1093/bioinformatics/17.10.977. View

13.

Naderi A, Ahmed A, Wang Y, Brenton J, Caldas C . Optimal amounts of fluorescent dye improve expression microarray results in tumor specimens. Mol Biotechnol. 2005; 30(2):151-4. DOI: 10.1385/MB:30:2:151. View

14.

Royston P, Altman D, Sauerbrei W . Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2005; 25(1):127-41. DOI: 10.1002/sim.2331. View

15.

Brenton J, Carey L, Ahmed A, Caldas C . Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol. 2005; 23(29):7350-60. DOI: 10.1200/JCO.2005.03.3845. View

16.

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

17.

Hu Z, Fan C, Oh D, Marron J, He X, Qaqish B . The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006; 7:96. PMC: 1468408. DOI: 10.1186/1471-2164-7-96. View

18.

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J . Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98(4):262-72. DOI: 10.1093/jnci/djj052. View

19.

Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6):560-9. DOI: 10.1056/NEJMoa052933. View

20.

Miller L, Smeds J, George J, Vega V, Vergara L, Ploner A . An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005; 102(38):13550-5. PMC: 1197273. DOI: 10.1073/pnas.0506230102. View